Geneva, Switzerland & Barcelona, Spain – 27th April, 2026 — ABCDx, a company developing blood-based diagnostic solutions for acute brain injuries, today announced the grant of two new patents in China and the United States, further reinforcing its international intellectual property portfolio.
The first patent, granted in China (CN114041058B), covers a method for selecting patients eligible for reperfusion therapy, a critical step in the treatment of acute ischemic stroke. The patent, valid until 2040, supports the clinical need for improved triage and faster identification of patients who may benefit from thrombectomy or other reperfusion interventions.
The second patent, granted in the United States (No. 12,601,748), relates to prospective biomarkers in traumatic brain injury (TBI). The patent includes a significant patent term adjustment, extending its duration and strengthening long-term protection in one of the world’s most important healthcare markets.
“These patent grants represent important milestones for ABCDx and validate the strength of our scientific and technological approach,” said Jean-Charles Sanchez, CEO and Co-founder of ABCDx. “They reinforce our ability to protect key innovations at the intersection of biomarkers, diagnostics, and clinical decision-making in acute brain injury.”
Together, these patents expand ABCDx’s protection across two major indications, stroke and traumatic brain injury, and in two strategic geographies. They contribute to a growing intellectual property portfolio supporting the company’s development of rapid, point-of-care diagnostic solutions combining biomarker panels with digital and AI-driven analysis.
The patented technologies originate from research conducted in collaboration with leading academic institutions, including the University of Geneva and the Vall d’Hebron Institute of Research.
ABCDx is currently advancing its diagnostic platform with the objective of improving early triage and patient selection in emergency settings, with a focus on accelerating access to appropriate care in time-critical conditions.
About ABCDx
ABCDx is a Swiss-Spanish diagnostics company developing blood-based tests for brain injury and acute neurological conditions. Its portfolio spans stroke, traumatic brain injury, and related indications, with a focus on rapid, objective, and clinically actionable biomarkers.
Media Contact
Tamara Sefcovicova
PR, Marketing and Office Operations Specialist
